The role of resistin and homocysteine in the progression of functional liver disorders in patients with non-alcoholic fatty liver disease

The aim of the research was to study the relationship between plasma concentrations of resistin and homocysteine and indicators of enzyme and pigment metabolism in patients with non-alcoholic fatty liver disease (NAFLD) and its combination with type 2 diabetes mellitus (DM-2). Materials and methods. A total of 90 patients were examined, including patients with NAFLD (n=20) and its combination with DM-2 with normal body weight (n=20) and obesity (n=50), as well as 20 healthy volunteers. A complex of clinical, laboratory and instrumental (including liver biopsy in 9 patients) examinations of patients was performed. Results. A direct relationship was established between the level of resistin and homocysteine and indicators of enzyme and pigment exchange in groups of patients with combined pathology. A significant increase of resistin and homocysteine plasma level, as well as disorders of the liver function were determined in all groups of patients in comparison with the controls. The most marked changes were revealed in patients with combination of NAFLD, DM-2 and obesity. Conclusions. The established relationship between the level of resistin, homocysteine and the indicators of the liver functional state suggests that an increase of resistin and homocysteine level may reflect the presence of impaired liver function in patients with NAFLD in combination with DM-2, predicting the progression of NAFLD. In order to detect the disorders of liver function in patients with DM-2, it is recommended to determine the level of resistin and homocysteine in patients with NAFLD, especially when concomitant obesity is present. Patients with resistin level (>8.06±0.23 ng/ml) and homocysteine level (>25.5±0.2 μmol/l) should be considered at risk of NAFLD progression.

неалкогольная жировая болезнь печени, сахарный диабет 2 типа, ожирение, резистин, гомоцистеин, Non-alcoholic fatty liver disease, type 2 diabetes, obesity, resistin, homocysteine